Don Tracy, Associate Editor

JAMA study indicates Canada may have a more resilient drug supply chain or different thresholds for reporting and responding to issues compared with the United States.

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses examples of how effective communication can resolve supply chain issues.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses how to handle opposing concerns between supply chain teams and offers communication solutions.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses critical conversations that supply chain teams and partners must partake in during API sourcing at LogiPharma USA 2024.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses key takeaways from the breakout session at LogiPharma USA 2024.

New facilities are expected to focus on manufacturing next-generation medicines and biologic medicines.

Session discusses the soft skills needed to ensure that communication strategies are being followed with distributors and other logistical partners across the value chain.

Results of the Phase III CENTERSTONE study demonstrated that when Xofluza is taken by an individual with influenza, it lowers the risk of others in the household contracting it.

Despite support from patient assistance programs and legislation designed to combat growing healthcare costs, challenges remain.

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.

The joint venture aims to disrupt pathological lncRNA interactions with RNA-binding proteins using NextRNA’s platform.

The new vials of Zepbound are available through a new self-pay pharmacy channel, priced over 50% lower than other incretin medications for obesity.

Chris Williams expands on the services that a third-party logistics (3PL) partner should offer, while sharing ways to alleviate standard supply chain issues.

The updated COVID vaccine replaces previous bivalent vaccines, focusing on a single strain for more effective immunity.

Investigators evaluate differences in end-of-life care between Medicare beneficiaries in Medicare Advantage vs. traditional Medicare.

FDA to review one-year results for Susvimo showing non-inferior visual acuity gains in diabetic macular edema and in the Diabetic Retinopathy Severity Scale for Diabetic Retinopathy.

New production line represents Rentschler Biopharma SE’s biggest investment in its 150-year history.

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

Results from the CORE-001 clinical trial are expected to be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law offers his thoughts on the recent Federal Trade Commission (FTC) repeal of non-compete agreements, and how it could effect the pharma industry.

Citing a need for more Chemistry Manufacturing and Controls information, Abeona intends to address the requirements quickly.

Deal gives Incyte access to Escient’s pipeline of oral MRGPR antagonists, including EP262 and EP547.

Approval comes amid positive results of a single-arm trial, showing a complete response rate of 77% in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Technology designed to effectively address blood clots by combining capabilities of larger devices with smaller catheters.

Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.

Data displayed rapid and sustained B-cell depletion, with 97.2% of study patients with relapsing and primary progressive multiple sclerosis experiencing no relapses.

Data from the Phase III APPLAUSE-IgAN study showed a 38.3% reduction in proteinuria in patients treated with Fabhalta for IgA nephropathy compared to placebo.

Company also purchased equipment for 12 good manufacturing practice clean rooms.